Oncolytics receives Canadian patent for methods to increase effectiveness of Reolysin cancer treatment

By E. Janene Geiss

Philadelphia, April 11 - Oncolytics Biotech Inc. said Tuesday that it has been granted Canadian Patent 2,415,750 entitled "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders." The claims describe methods for preventing reovirus recognition by the host immune system, while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells.

"The claims in this Canadian patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," Matt Coffey, chief scientific officer of Oncolytics, said in a company news release.

The Canadian patent follows a U.S. patent for the treatment that the company said it received recently.

Reolysin is the company's proprietary formulation of the human reovirus, used as a cancer treatment alone and in combination with radiation.

Oncolytics is a Calgary, Alta.-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.